Idiopathic pulmonary fibrosis (IPF) is an interstitial lung disease characterised by chronic,
progressive scarring of the lungs and the pathological hallmark of usual interstitial …

Idiopathic pulmonary fibrosis (IPF) is a fibrotic interstitial lung disease associated with
significant morbidity and mortality. Previously, IPF has been managed using …

Background Real-life data on the use of pirfenidone and nintedanib to treat patients with
idiopathic pulmonary fibrosis (IPF) are still scarce. Methods We compared the efficacy of …

Along with increasing age and male sex, potential risk factors for IPF include cigarette
smoking, environmental exposures, microbial pathogens, and genetic factors. 1 Anyone with …

Idiopathic pulmonary fibrosis (IPF) is an inexorably progressive lung disease of unknown
origin. Prognosis is poor, with limited treatment options available, and the median survival …

Objective: Provide information for pharmacists on idiopathic pulmonary fibrosis (IPF) and its
treatment. Study Selection and Data Extraction: All articles with data from randomized …

Sex and gender differences influence key domains of research, lung health, healthcare
access and healthcare delivery. In interstitial lung diseases (ILDs), mouse models of …

Nintedanib is a tyrosine kinase inhibitor approved for the treatment of idiopathic pulmonary
fibrosis (IPF). In a retrospective, real-world study across seven Greek hospitals, we …

Background Phase 3 trials have shown that nintedanib reduces the decline in forced vital
capacity (FVC) in patients with mild-to-moderate idiopathic pulmonary fibrosis (IPF) with …

Introduction Nintedanib is recommended for the treatment of idiopathic pulmonary fibrosis
(IPF); however, treatment discontinuation due to adverse events (AEs) is common. A large …